Vivesto Ab · OMXSTO:VIVE
Vivesto Ab — Oasmia Pharmaceutical — Q2 2021 Earnings Presentation
17 slides from Vivesto Ab's earnings presentation, Aug 19, 2021
Slide 1: Q2 and Interim Results (1 Jan – 30 Jun 2021)
Q2 AND INTERIM RESULTS (1 JAN – 30 JUN 2021) Francois Martelet M.D., CEO and Fredrik Järrsten, CFO 19 August 2021 1
Slide 2: Forward-looking statement
Forward-looking statement IMPORTANT NOTICE The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require p
Slide 3: Today's speakers
Today’s speakers FRANCOIS MARTELET, M.D. FREDRIK JÄRRSTEN Chief Executive Officer Chief Finance Officer 3
Slide 4: Significant events during the quarter
Significant events during the quarter Corporate highlights • Nordic commercialization rights for Apealea® transferred to Inceptua Group • Dr Reinhard Koenig appointed as Chief Scientific Officer • Andrea Buscaglia proposed as a new Board member by the Nomination Committee • Senior level management p
Slide 5: Q2 report – key figures
Q2 report – key figures Key figures Q2-21 Q2-20 H1-21 H1-20 2020 • Net sales in Q2 relating to sales of finished products from our Jan-Dec inventory to Elevar in preparation for the PK study Net sales, TSEK 4 596 254 4 633 201 474 201 760 • Operating costs, defined as other external expenses and Ope
Slide 6: Clearly defined strategy to drive growth 2021 – 2023
Clearly defined strategy to drive growth 2021 – 2023 Expand development pipeline through M&A/in-licensing Execute on Elevar/Apealea development development/ Oasmia 2.0 pipeline – royalties Cantrixil, Docetaxel micellar Leverage technology platforms for internal development, out- licensing 6
Slide 7: An emerging oncology portfolio
An emerging oncology portfolio Registration / Commercial Product Indication Pre-clinical Phase 1 Phase 2 Phase 3 approval Launch Geography Human Health Portfolio Apealea® / Ovarian cancer EU / EEA Paclical® (paclitaxel)* Ovarian cancer USA Cantrixil Ovarian cancer Global Docetaxel Prostate cancer EU
Slide 8: M&A and/or in-licensing opportunities
M&A and/or in-licensing opportunities • Business development activities stepped up in quarter • Currently undertaking or have performed due diligence on several oncology companies with several active projects ongoing • We’re looking to in-license global oncology products from pre-clinical up to late
Slide 9: Exploring the full potential of our technologies
Exploring the full potential of our technologies Project Objective Discovery Feasibility Development Validation Launch Solubilization platform XR-17™ Out licensing and sales Next generation of XR-18 XR-17 Target 2023 Out licensing and sales Solubilization platform XR-19 – dual encapsulation Target 2
Slide 10: Apealea commercialisation – out-licensed to Elevar and its partners
Apealea® commercialisation – out-licensed to Elevar and its partners Worldwide Peak sales estimates ~$275m - $282m Europe (ovarian cancer1) USA Commercialization agreement signed • Pathway to commercialization identified between Elevar Therapeutics and Inceptua and being executed by Elevar Group Asi
Slide 11: Cantrixil status and plans
Cantrixil status and plans • Cantrixil is a tubulin-binding small molecule with potent cytotoxicity against CD 44+ ovarian cancer stem cells, ovarian somatic cancer cells (CD 44+), both resistant to standard chemotherapies • In-licensed from Kazia in 2021 and is being developed in advanced ovarian c
Slide 12: Cantrixil formulation research using XR-17 and XR-18
Cantrixil formulation research using XR-17 and XR-18 • Oasmia will initiate formulation research with Cantrixil in 2021 with the goal to improve certain properties of the compound • Cantrixil will be the first API to be screened for formulation with our proprietary platforms Research objectives: • E
Slide 13: Docetaxel micellar – Phase 1b in prostate cancer ongoing
Docetaxel micellar – Phase 1b in prostate cancer ongoing • Phase 1b trial ongoing with SAKK (Swiss Group for Clinical Cancer Research) ‒ Open-label, multicenter, single-stage trial at major 1 hospitals in Switzerland ‒ Recruiting 18 chemotherapy-naïve patients with metastatic castration resistant pr
Slide 14: Implementing the highest ESG standards
Implementing the highest environmental, social and governance (ESG) standards Structure to support Oasmia’s sustainability work: • The Board is responsible for ensuring that sustainability is adequately addressed within the Company. The CEO is responsible for implementation. All employees are respon
Slide 15: Determining our focus and priorities in ESG
Determining our focus and priorities in ESG Sound work Culture Attract and HIGH environment retain talent Good governance Business ethics Minimize Responsible operational supply chain environmental footprint Climate Cyber security Risk How material is Resource management the aspect efficiency Chemic
Slide 16: Potential near- and mid-term value drivers 2021 – 2023
Potential near- and mid-term value drivers 2021 – 2023 • Continued evaluation of M&A and in-licensing opportunities to build critical mass in oncology • Cantrixil – trial design, KOL recruitment and supply agreement for Phase 2 (2022) • Docetaxel micellar – Phase 1b completion • Apealea® – partnerin
Slide 17: Thank you!
Thank you! Oasmia Pharmaceutical AB (STO: OASM) +46 018-50 54 40 www.linkedin.com/comp Vallongatan 1 any/oasmia- 752 28 Uppsala IR@oasmia.com pharmaceutical-ab Sweden www.oasmia.com www.twitter.com/Oasmia
Oasmia Pharmaceutical — Q2 2021 Earnings Presentation on 6ix